Information Provided By:
Fly News Breaks for September 23, 2016
MYL
Sep 23, 2016 | 07:17 EDT
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
News For MYL From the Last 2 Days
There are no results for your query MYL